Prana Biotechnology LTD Sample Contracts

WITNESSETH
Settlement Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
ALTERITY THERAPEUTICS LIMITED American Depositary Shares each representing 600 fully paid Ordinary Shares Sales Agreement
Alterity Therapeutics LTD • February 15th, 2024 • Pharmaceutical preparations • New York

Alterity Therapeutics Limited, a corporation incorporated under the laws of Australia (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:

Deposit Agreement Dated as of March 23, 2001
Deposit Agreement • December 21st, 2007 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
Project Agreement
Project Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • November 13th, 2020 • Alterity Therapeutics LTD • Pharmaceutical preparations • New York

This Agreement is made pursuant to each Confirmation Letter, dated as of the date hereof, between A.G.P./Alliance Global Partners, as U.S. Selling Agent for a private placement of ordinary shares and options of the Company, and each Purchaser (the “Confirmation Letters”). Capitalized terms used and not otherwise defined herein that are defined in the Confirmation Letters shall have the meanings given such terms in the Confirmation Letters.

March 23, 2001
Prana Biotechnology LTD • August 28th, 2006 • Pharmaceutical preparations
AMENDMENT NO. 1 TO AT MARKET ISSUANCE SALES AGREEMENT
Prana Biotechnology LTD • November 8th, 2017 • Pharmaceutical preparations • New York

Prana Biotechnology Ltd (the “Company”), B. Riley FBR, Inc. (successor by merger to FBR Capital Markets & Co.) (“B. Riley FBR”) and JonesTrading Institutional Services LLC (“JonesTrading” and together with B. Riley FBR, the “Agents”) are parties to that certain At Market Issuance Sales Agreement dated October 13, 2016 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows (to be effective as set forth in paragraph 6 below):

Master Services Agreement
Master Services Agreement • August 26th, 2015 • Prana Biotechnology LTD • Pharmaceutical preparations • Delaware

This Master Services Agreement (this “Agreement”) is made and entered into as of the date of the last party to sign (the “Effective Date”) between Certara, L.P., a Delaware limited partnership, via its branch, Certara, L.P. Sucursal em Portugal (hereinafter “Certara Portugal”), and Prana Biotechnology Ltd ACN 080 699 065, an Australian public company with its principal office at Level 2, 369 Royal Parade, Parkville, Victoria 3052 Australia (hereinafter “Customer”).

WORK AUTHORISATION Reference: WA002 (PBT2-204)
Prana Biotechnology LTD • October 22nd, 2013 • Pharmaceutical preparations

This Work Authorisation is between Prana Biotechnology Limited of Level 2, 369 Royal Parade, Parkville, VIC 3052, Australia (hereinafter “Customer”) and INCResearch Australia Pty Limited ACN 080 425 387 & ABN 67 080 425 387, 124 Lipson Street, Port Adelaide 5015 SA (hereinafter “INC”) and relates to the Master Services Agreement dated 28th September 2011, (the “Master Agreement”). Pursuant to the Master Agreement, INC has agreed to provide certain services in accordance with written work authorisations, such as this one, entered into from time-to-time describing such services.

EMPLOYMENT AGREEMENT
Employment Agreement • September 29th, 2006 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria

THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of date of signing between Prana Biotechnology Limited, an Australian corporation (the “Company”) with its principal offices at Level 2, 369 Royal Parade, Parkville, Victoria, Australia, and Ross Murdoch (the “Executive”), residing at 53 Kingston Street, Hampton, 3188, Victoria, Australia.

PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENT
Development and Manufacturing Agreement • September 24th, 2009 • Prana Biotechnology LTD • Pharmaceutical preparations • England

This PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENT (hereinafter “Agreement”) is made by and between Prana Biotechnology Ltd ACN 080 699 065 (“Prana”), a company incorporated in Australia whose registered office and principal place of business is at Level 2,369 Royal Parade, Parkville Victoria 3052 and Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a company incorporated and existing under the laws of India, having its principal place of business at 7-1-27 Ameerpet Hyderabad 500 016 India.

FIFTH RESEARCH FUNDING AND INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT BETWEEN UNIVERSITY OF MELBOURNE AND PRANA BIOTECHNOLOGY LTD (ABN 37 080 699 065)
Assignment Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria

THE UNIVERSITY OF MELBOURNE [ABN 84 002 705 224] of Parkville, Victoria 3010, a body politic and corporate pursuant to the provisions of the University of Melbourne Act 2009 (Vic) (University)

EMPLOYMENT AGREEMENT
Employment Agreement • December 21st, 2005 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria

THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated as of 15 June, 2005, between Prana Biotechnology Limited, an Australian corporation (the “Company”) with its principal offices at Level 2, 369 Royal Parade, Parkville, Victoria, Australia, and Geoffrey Kempler (the “Executive”), residing at 19 Crotonhurst Avenue North Caulfield 3161, Victoria, Australia.

Master Services Agreement
Master Services Agreement • October 4th, 2016 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria

Prana Biotechnology Ltd ACN 080 699 065 of Level 2, 369 Royal Parade, Parkville Victoria Australia 3052 (Prana) (each a party and collectively, the parties)

MANUFACTURING SERVICES AGREEMENT FOR PBT2 HCI SUPPLY
Manufacturing Services Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • London

This MANUFACTURING SERVICES AGREEMENT (hereinafter called “Agreement”) is made on this 19 day of August, 2013 by and between Prana Biotechnology Ltd ACN 080 699 065 (“Prana”), a company incorporated in Australia whose registered office and principal place of business is at Level 2,369 Royal Parade, Parkville Victoria 3052 and Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a company incorporated and existing under the laws of India, having its principal place of business at # 8-2-337, Road No.3, Banjara Hills, Hyderabad 500 034, Andhra Pradesh, India.

WORK ORDER INC Research Project # 1000504 Protocol # PBT2-203
Prana Biotechnology LTD • October 22nd, 2013 • Pharmaceutical preparations

This Work Order (hereinafter “Work Order”) is between Prana Biotechnology Limited (hereinafter “Sponsor”) with principal offices located at Level 2, 369 Royal Parade, Parkville VIC 3052 Australia and INCResearch Australia Pty Limited, together with its parent company, subsidiaries and legal affiliates (hereinafter “INC Research”) with offices located at 124 Lipson Street, Port Adelaide SA 5015 Australia and relates to the Master Services Agreement effectively dated 22nd September 2011 which expressly incorporates this Work Order hereto by reference into the Master Services Agreement. Pursuant to the Master Services Agreement, INC Research has agreed to perform certain services in accordance with written work orders, such as this one, entered into from time to time describing such services.

Amendment No. 2 to At-The-Market Issuance Sales Agreement
Prana Biotechnology LTD • November 26th, 2014 • Pharmaceutical preparations • New York
MASTER SERVICES AGREEMENT FOR PROVISION OF CLINICAL RESEARCH SERVICES Between INCResearch Australia Pty Limited (ABN 67 080 425 387) of 124 Lipson Street, Port Adelaide, South Australia 5015, Australia (INC) And Prana Biotechnology Limited (ABN...
Master Services Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria

INTRODUCTION The Customer has requested and INC has agreed to provide the Services to the Customer. In consideration for the provision of the Services the Customer has agreed to pay INC the Services Fee. OPERATIVE CLAUSES PART 1 – PRELIMINARY 1. Definitions In this Agreement: 1.1 “Address” means the addresses of the Customer and INC specified in Item 3 of Schedule 1, or such other address as may be notified; 1.2 “Affiliates” means a related body corporate within the meaning of the Corporations Act (Cth) 2001; 1.3 “Business Day” means any day except a Saturday or a Sunday or other public holiday in South Australia; 1.4 “Business Records” means a record of: 1.4.1 the functions, decisions and meetings of the board of the Customer; 1.4.2 the conduct of the Customer’s Operations; 1.4.3 the outgoings in respect of the Customer’s Operations; 1.4.4 all marketing, advertising or promotions conducted by the Customer; and 1.4.5 all other information kept in respect of the Customer’s Operations as

Amendment 14 to Agreement dated 26th Dec’08 signed by and between
To Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations

This amendment will include the following additional and amended clauses in the above mentioned Agreement (plus amendments) and will be in effect from 18 September 2012.

AutoNDA by SimpleDocs
WORK ORDER
Prana Biotechnology LTD • October 22nd, 2013 • Pharmaceutical preparations

This Work Order (hereinafter “Work Order”) is between Prana Biotechnology Limited (hereinafter “Sponsor”) with principal offices located at Level 2, 369 Royal Parade, Parkville VIC 3052 Australia and INCResearch Australia Pty Limited, together with its parent company, subsidiaries and legal affiliates (hereinafter “INC Research”) with offices located at 124 Lipson Street, Port Adelaide SA 5015 Australia and relates to the Master Services Agreement effectively dated 22nd September 2011 which expressly incorporates this Work Order hereto by reference into the Master Services Agreement. Pursuant to the Master Services Agreement, INC Research has agreed to perform certain services in accordance with written work orders, such as this one, entered into from time to time describing such services.

Amendment 1 to Agreement dated 19th Aug’13 signed by and between Dr. Reddy’s Laboratories Limited Bollaram Road, Miyapur, Hyderabad 500 049 India (Hereinafter referred to as “Dr. Reddy’s”) and Prana Biotechnology Ltd Level 2,369 Royal Parade,...
To Agreement • November 3rd, 2014 • Prana Biotechnology LTD • Pharmaceutical preparations

This amendment will include the following amended clauses in the above mentioned agreement and will be in effect from 26th September 2013.

D3 MEDICINE LLC MASTER SERVICES AGREEMENT
Master Services Agreement • August 26th, 2015 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria

This Master Services Agreement (this “Agreement”), effective 17 March, 2015 (the “Effective Date”), is entered into by and between d3 Medicine LLC, a limited liability company having offices at 4 Century Drive, 2nd Floor, Parsippany, NJ 07054, United States of America (“d3”) and Prana Biotechnology Ltd ACN 080 699 065, a limited liability company having offices at Level 2, 369 Royal Parade, Parkville Victoria 3052 (“Client”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). In consideration of the covenants and conditions contained herein, the Parties hereby agree to the following:

CHANGE ORDER N°1 to Work Order #1002213
Prana Biotechnology LTD • November 3rd, 2014 • Pharmaceutical preparations

This Change Order number 1 to Work Order #1002213 (hereinafter “Change Order”) is made and entered into as of the date of last signature (hereinafter “Effective Date”) by and between Prana Biotechnology Limited (hereinafter “Sponsor”) with an office located at Level 2, 369 Royal Parade, Parkville VIC 3052 Australia and INCResearch Australia Pty Limited, together with its parent company, subsidiaries and legal affiliates (hereinafter “INC Research”) with offices located at 124 Lipson Street, Port Adelaide SA 5015, Australia.

AMENDMENT to the Clinical Trial Agreement between Prana Biotechnology Limited and The University of Rochester
Prana Biotechnology LTD • November 3rd, 2014 • Pharmaceutical preparations

WHEREAS, The University of Rochester (“Institution”) and Prana Biotechnology Limited (“Sponsor”) have entered into a Clinical Trial Agreement dated October 7, 2011 relating to clinical trial services with regard to the product PBT2 (“Agreement”), and

AGREEMENT
Agreement • November 9th, 2010 • Prana Biotechnology LTD • Pharmaceutical preparations

This Agreement is made and dated as of June 23, 2010 (this “Agreement”) between Quintiles Limited (“Quintiles”) and Prana Biotechnology Limited (“Prana”). Each of Quintiles and Prana may be referred to herein as a “Party” and collectively as the “Parties.”

Clinical Research Support Agreement
Prana Biotechnology LTD • October 4th, 2012 • Pharmaceutical preparations

The General Hospital Corporation d/b/a Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, United States of America (MGH)

PRANA BIOTECHNOLOGY LTD American Depositary Shares each representing 10 fully paid Ordinary Shares At-The-Market Issuance Sales Agreement
Prana Biotechnology LTD • July 13th, 2011 • Pharmaceutical preparations • New York

Prana Biotechnology Ltd, a corporation incorporated under the laws of the state of Victoria, Australia (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), as follows:

Prana Biotechnology Limited Level 2, 369 Royal Parade, Parkville
Prana Biotechnology LTD • October 22nd, 2013 • Pharmaceutical preparations
AMENDMENT NO. 2 TO AT MARKET ISSUANCE SALES AGREEMENT
Market Issuance Sales Agreement • December 16th, 2020 • Alterity Therapeutics LTD • Pharmaceutical preparations • New York

Alterity Therapeutics Limited (formerly Prana Biotechnology Ltd) (the “Company”), B. Riley Securities, Inc. (formerly B. Riley FBR, Inc. (successor by merger to FBR Capital Markets & Co.)) (“B. Riley”) and JonesTrading Institutional Services LLC (“JonesTrading” and together with B. Riley, the “Agents”) are parties to that certain At Market Issuance Sales Agreement dated October 13, 2016, as amended on November 8, 2017 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

Amendment 1.3 to Agreement dated 26th Dec ’08 signed by and between Dr. Reddy’s Laboratories Limited Bollaram Road, Miyapur, Hyderabad 500 049 India (Hereinafter referred to as “Dr. Reddy’s”) And Prana Biotechnology Ltd Level 2, 369 Royal Parade,...
Agreement • October 4th, 2012 • Prana Biotechnology LTD • Pharmaceutical preparations

This amendment will include the following additional and amended clauses in the above mentioned Agreement (plus amendments) and will be in effect from 14 February 2012 onwards.

Amendment No. 1 to At-The-Market Issuance Sales Agreement
Prana Biotechnology LTD • August 30th, 2013 • Pharmaceutical preparations • New York
SECOND RESEARCH FUNDING AND INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT BETWEEN UNIVERSITY OF MELBOURNE AND PRANA BIOTECHNOLOGY LTD (ABN 37 080 699 065)
Assignment Agreement • September 29th, 2006 • Prana Biotechnology LTD • Pharmaceutical preparations

THE UNIVERSITY OF MELBOURNE [ABN 84 002 705 224] of Parkville, Victoria 3010, a body politic and corporate pursuant to the provisions of the Melbourne The University Act 1958 ("the University").

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!